🚨 We’re excited to share our newest Rapid Resource—VTE Prophylaxis After Trauma, developed with CNTR. This 2-page summary details best practices for VTE prophylaxis after trauma, applicable to patients ≥15 years or post-pubertal children with high injury severity. 👉 View it here: bit.ly/49xW7wL

Today's the Day! #ATHNDataSummit2025 kicks off today at 11 am ET. Make sure you're a part of it! athn.org/events/data-...

Today's a great day to register! athn.org/events/data-...

Don’t miss out! There’s still time to submit your abstract by July 25th! #ATHNDataSummit2025 #CallforAbstracts <<https://athn.org/events/data-summit.html>>

Don’t miss out! There’s still time to submit your abstract to us by July 25th! #ATHNDataSummit2025 #CallforAbstracts <<https://athn.org/events/data-summit.html>>

Don’t miss out! There’s still time to submit your abstract to us by July 25th! #ATHNDataSummit2025 #CallforAbstracts <<https://athn.org/events/data-summit.html>>

Drs. Tami Singleton and Ali Mokdad slaying it at the interactive VWD "meet the experts" session at #ISTH2025

Our superstars Dr. Kate Pratt and Dr. Niki Machin rockin #ISTH2025 with their poster on the Transcends INHIBIT module. athn.org/what-we-do/n...

Don't miss this fascinating presentation at #ISTH2025

Hello #hemesky folks! #ISTH2025 is coming up fast, so show me your abstracts! I'm planning my schedule now, tell me where to learn about your work. @shematologist.medsky.social @dianvanderwaldr.bsky.social @samelsonjones.bsky.social @jhmorrissey.bsky.social I think I saw your names in the program. 👀

Join ATHN at the ISTH 2025 Congress! ATHN is proud of our many presenters who will be sharing their research updates and insights at the ISTH 2025 Congress in Washington, D.C., June 21-25. Two oral presentations and nine poster presentations!

Help us learn more about Hemophilia B! New research study open studying the safety and effectiveness of Rebinyn® (Coagulation Factor IX (Recombinant) GlycoPEGylated). Learn how to join today! gothemophiliab.com/hemophiliab....

Got Hemophilia B? If you take Coagulation Factor IX (Recombinant) GlycoPEGylated (Rebinyn®) you could join a research study looking at long-term safety and effectiveness. Interested? Find out more: gothemophiliab.com/hemophiliab....

Help us learn more about Hemophilia B! New research study open studying the safety and effectiveness of Rebinyn® (Coagulation Factor IX (Recombinant) GlycoPEGylated). Learn how to join today! gothemophiliab.com/hemophiliab....

@ATHN.org

gothemophiliab.com/hemophiliab.... Got Hemophilia B? If you take Coagulation Factor IX (Recombinant) GlycoPEGylated (Rebinyn®) you could join a research study looking at long-term safety and effectiveness. Interested?

gothemophiliab.com/hemophiliab.... Got Hemophilia B? If you take Coagulation Factor IX (Recombinant) GlycoPEGylated (Rebinyn®) you could join a research study looking at long-term safety and effectiveness. Interested?

Learn more: athn.org/events/data-...

Are you interested in Hemophilia B research? ATHN (American Thrombosis and Hemostasis Network) has a research study about treatment and safety of Coagulation Factor IX (Recombinant) GlycoPEGylated (Rebinyn®). If you join the study, you can help us learn more! gothemophiliab.com/hemophiliab....

We invite you to join a research study focusing on bleeding symptoms and treatment outcomes for people with Glanzmann Thrombasthenia. Adding your data to the study will enhance research to find better treatments! Learn more: bit.ly/4eYlQgT

@ATHN.org

Don't miss this important webinar featuring ATHN's own Dr. Tami Singleton!

Hemab Therapeutics, who we partnered with for our VWD360 study, have announced a Phase 1/2 clinical trial for a subcutaneous treatment for all types of #vonWillebrandDisease. Learn more here: loom.ly/ObYxgZo. Or for more information about trial participation: loom.ly/NiyJ3lg #HemeSky #MedSky

At ATHN, we are about people suffering from rare disease. Learn more about ATHN and our ATHN 10 study at www.athn.org

Learn more here: athn.org/what-we-do/n...

Mark your calendars for another ATHN Data Summit!

So proud of Dr. Tammuella Chrisentery-Singleton on being recognized by the American Heart Association and Women in STEM New Orleans. @athnnews.bsky.social

Big news!

Just your regular reminder that ~40% of menstruating adolescents (and likely even higher proportion of adults) suffer from iron deficiency and yet we don’t universally screen. jamanetwork.com/journals/jam...

Everyone at #ASH2024 is having a great time including our very own Dr. Tami Singleton! Thanks Bayer for a fascinating poster!

At ATHN, we are dedicated to improving the lives for people with blood disorders - using data to fuel research that leads to discovery. Learn more: athn.org.

Thank you for this helpful information!

A new paper on our GT360 study is now published in Haemophilia journal: loom.ly/WXSU0ZU Our blog and animated video summarise the findings, based on in-depth interviews with people who live with Glanzmann's Thrombasthenia: loom.ly/KsAddKU #HemeSky #GlanzmannThrombasthenia #BleedingDisorders

Top three hematology pearls for pediatricians #medsky #hemesky 1. Serum iron level is useless 2. Thrombocytosis is reactive 99% of the time 3. Percentage values on WBC differential don’t matter, only absolute values

Have you heard about ATHN Transcends? Learn more: athn.org/what-we-do/n...

So nice to see all the new friends at Blue Sky!

Congratulations St. Joseph's Hospital Center for Bleeding and Clotting Disorders for a successful OneDrop Event hosted by CHES Foundation! Pictured: Janet Brewer, Erin Cockrell, MD, Lissette Sanchez, Cindy Manis, Jennifer Manns, and Olivia Galler.

Hello Blue Sky. ATHN here. Glad to have a platform to talk about hematology, blood disorders and improving care for patients.